. 2024 Jan 27;11(3):100386. doi: 10.1016/j.apjon.2024.100386

Table 1.

General characteristics of the included literature (N = 10).

Included literature	Topic	Year	Source	Type of evidence
Elad et al.¹¹	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy	2020	PubMed	Clinical practice guideline
Peterson et al.¹²	Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up	2015	PubMed	Clinical practice guideline
Steinmann et al.¹³	Nursing procedures for the prevention and treatment of mucositis induced by cancer therapies	2021	PubMed	Clinical practice guideline
Ma et al.¹⁴	Practice guideline for cancer symptom management in China - oral mucositis	2020	CNKI	Clinical practice guideline
Chinese Society for Radiation Oncology¹⁵	Expert consensus on strategies for prevention and treatment of radiotherapy-induced oral mucositis	2019	Wanfang	Expert consensus
Chinese Society of Clinical Oncology et al.¹⁶	Expert consensus on diagnosis and prevention of acute oral mucositis caused by antitumor therapy	2021	CNKI	Expert consensus
UKOMIC¹⁷	Oral care guidance and support in cancer and palliative care	2019	UKOMIC	Expert consensus
Whitehorn et al.¹⁸	Oral mucositis: Prevention and management principles	2021	JBI	Evidence summary
An et al.¹⁹	Role of honey in preventing radiotherapy-induced oral mucositis	2021	PubMed	Systematic review
Tian et al.²⁰	Impact of honey on radiotherapy-induced oral mucositis in patients with head and neck cancer	2020	PubMed	Systematic review

ESMO, European Society for Medical Oncology; MASCC/ISOO, Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology; UKOMIC, United Kingdom Oral Management in Cancer Group.